SCHEMBL6419255

SCHEMBL6419255

N/N=C(\c1cc(Cl)ccc1O)c1nc2nonc2nc1Nc1ccc(F)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
POLB P06746 3/20 0.39
TP53 P04637 2/20 0.39
CCR2 P41597 1/20 0.37
CCR5 P51681 1/20 0.37
BRAF P15056 2/20 0.37
GRM4 Q14833 2/20 0.36
SOS1 Q07889 2/20 0.36
EGFR P00533 4/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.35
KDR P35968 1/20 0.35
HTT P42858 1/20 0.35
ERBB2 P04626 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419263 1.00 MAPT (0.39) MAPTSMN1; SMN2POLBTP53CCR2
SCHEMBL6419775 0.90 MAPT (0.39) MAPTSMN1; SMN2POLBTP53CCR2
SCHEMBL6419767 0.90 MAPT (0.39) MAPTSMN1; SMN2POLBTP53CCR2
SCHEMBL6418411 0.90 P2RX1 (0.41) MAPTSMN1; SMN2POLBTP53CCR2
SCHEMBL6418425 0.90 P2RX1 (0.41) MAPTSMN1; SMN2POLBTP53CCR2
SCHEMBL6417864 0.90 APP (0.42) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL6414239 0.88 MAPT (0.37) MAPTSMN1; SMN2POLBTP53CCR2
SCHEMBL6414240 0.88 MAPT (0.37) MAPTSMN1; SMN2POLBTP53CCR2
SCHEMBL6418364 0.87 TP53 (0.43) MAPTSMN1; SMN2POLBTP53CCR2
SCHEMBL6418345 0.87 TP53 (0.43) MAPTSMN1; SMN2POLBTP53CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885SMN1; SMN2 4369/4885POLB 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.